Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 36.33M | 35.80M | 26.34M | 20.15M | 9.50M | 7.91M |
Gross Profit | -2.14M | -1.68M | 12.43M | 3.91M | 1.90M | 6.15M |
EBITDA | -17.26M | -19.45M | 4.84M | -1.89M | -9.65M | -5.07M |
Net Income | -20.72M | -22.55M | -5.07M | -7.54M | -11.23M | -10.17M |
Balance Sheet | ||||||
Total Assets | 56.35M | 59.47M | 82.55M | 67.03M | 50.57M | 40.80M |
Cash, Cash Equivalents and Short-Term Investments | 997.00K | 1.74M | 794.00K | 6.78M | 14.49M | 625.00K |
Total Debt | 16.04M | 17.01M | 18.70M | 3.01M | 623.00K | 7.50M |
Total Liabilities | 24.38M | 26.62M | 33.22M | 18.79M | 2.70M | 12.38M |
Stockholders Equity | 31.97M | 32.85M | 49.33M | 43.92M | 47.87M | 28.42M |
Cash Flow | ||||||
Free Cash Flow | 321.00K | 401.00K | 1.85M | -4.90M | -6.22M | -1.12M |
Operating Cash Flow | 429.00K | 507.00K | 5.41M | -3.46M | -5.62M | -357.00K |
Investing Cash Flow | -89.00K | -78.00K | -7.03M | -3.10M | -1.65M | -1.38M |
Financing Cash Flow | -88.00K | 539.00K | -4.38M | -993.00K | 20.96M | 393.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | C$6.41M | 181.82 | -3.45% | ― | 4.04% | 80.24% | |
58 Neutral | C$12.39M | 6.82 | 9.27% | ― | 15.54% | ― | |
51 Neutral | $9.13M | ― | -63.75% | ― | 9.34% | 69.69% | |
48 Neutral | C$8.55M | ― | -51.80% | ― | 32.63% | -90.15% | |
46 Neutral | C$194.28M | -4.22 | -8.60% | 2.64% | 13.54% | -1.44% |
Avant Brands Inc. has announced strategic international supply agreements to export up to 2,000 kilograms per year of GACP-certified, non-irradiated dried flower to the European medical cannabis market, enhancing its global market presence. Additionally, Avant is expanding its product offerings in Canada with over 30 new SKU listings in Ontario and B.C., introducing innovative packaging and products, and relaunching its medical division to better serve Canadian patients and veterans, marking a pivotal moment in its growth trajectory.
Avant Brands Inc. held its 2025 Annual General Meeting, where 16.19% of its common shares were represented. Key outcomes included the election of six directors, re-appointment of Ernst & Young LLP as auditors, and approval of amendments to the company’s deferred share unit and long-term incentive plans. Additionally, the repricing of certain warrants and convertible debentures was approved, reflecting strategic adjustments to enhance shareholder value and operational flexibility.
Avant Brands Inc. has announced its upcoming annual general and special meeting of shareholders, scheduled for May 30, 2025. The meeting will address several key business items, including the approval of repricing amendments to the exercise price of certain warrants and the conversion price of debentures, which were previously issued in a private placement. These amendments, aimed at adjusting the financial terms of the debentures and warrants, are subject to shareholder and Toronto Stock Exchange approval. This move could potentially impact Avant’s financial strategy and market positioning, offering more favorable terms to stakeholders involved in these financial instruments.
Avant Brands reported strong financial results for Q1 2025, with significant increases in gross and net revenue, driven by robust international demand for its premium cannabis products. The company achieved a 41% increase in export wholesale revenue, particularly in markets like Australia, Germany, and Israel. Despite a decline in recreational and domestic wholesale revenue due to strategic realignment, Avant continues to focus on scaling its global footprint and delivering sustainable long-term value.